7
05, 2020
31
07, 2019
2
05, 2019
29
04, 2019
11
04, 2019
19
03, 2019
14
02, 2019
Lorenza Rimassa et al., Phase 2 study of tivantinib and cetuximab in KRAS wild-type metastatic colorectal cancer patients with acquired resistance to EGFR inhibitors and emergence of MET overexpression: lesson learned for future trials with EGFR/MET dual inhibition
Diatech Pharmacogenetics2020-01-22T12:34:32+01:00
15
11, 2018
9
11, 2018
9
10, 2018